Biogen Volatile After Q3 Beat, Raised Guidance And Disappointing Phase 3 Study

Biogen Inc BIIB shares were trading higher by $10 at $275.81 in Wednesday's session. The Street is putting more emphasis on the Q3 beat and raised guidance as opposed to poor results from a Phase 3 study for Natalizumab. After higher open, it rallied to $291.01 before reversing course. The ensuing decline took the issue beyond Tuesday's low ($264.58), reaching $262.45 before rebounding into the mid-$270 handle.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!